Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.

Recombinant interleukin-2 (rIL-2) was used to treat 31 patients with progressing metastatic malignant melanoma. Only three patients had disease confined to non-visceral sites; the median number of organ sites involved was four. The first dose of rIL-2 was given intrasplenically (to stimulate cytotox...

Descripción completa

Detalles Bibliográficos
Autores principales: Thatcher, N., Dazzi, H., Johnson, R. J., Russell, S., Ghosh, A. K., Moore, M., Chadwick, G., Craig, R. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247307/
https://www.ncbi.nlm.nih.gov/pubmed/2803954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247307/
https://www.ncbi.nlm.nih.gov/pubmed/2803954

Ejemplares similares